Image

Global Cardiovascular Genetic Testing Market - Industry Trends and Forecast to 2030

Healthcare

Image

Global Cardiovascular Genetic Testing Market - Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Cardiovascular Genetic Testing Market - Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 7336.36 Million
Diagram Market Size (Forecast Year) USD 17152.16 Million
Diagram CAGR %

Global Cardiovascular Genetic Testing Market, By Disease (Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Testing Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others) – Industry Trends and Forecast to 2030.

Cardiovascular Genetic Testing Market

Cardiovascular Genetic Testing Market Analysis and Size

The global cardiovascular genetic testing market is a significant component of the broader genetic testing industry and is focused on identifying genetic factors related to cardiovascular diseases. Cardiovascular genetic testing helps assess an individual's genetic predisposition to cardiovascular diseases, such as coronary artery disease, hypertension, and cardiomyopathies. This information can guide healthcare professionals in tailoring preventive strategies and treatments. Genetic testing can identify individuals at higher risk of developing cardiovascular diseases at an early stage. This allows for more timely interventions and lifestyle modifications to prevent or delay disease progression and due to all these factors, there will be an upsurge in the growth of the global cardiovascular genetic testing market.

Data Bridge Market Research analyses that the global cardiovascular genetic testing market which was USD 7,336.36 million in 2022, expected to reach USD 17,152.16 million by 2030, and is expected to undergo a CAGR of 11.2% during the forecast period 2023-2030. “Inherited cardiomyopathies” dominates the disease segment of the global cardiovascular genetic testing market owing to the growing demand for better methods of bone related treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cardiovascular Genetic Testing Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Disease (Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, and Others), Technology(Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Testing Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others)

Countries Covered

U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher (U.S.), Daan Gene Co., Ltd. (Canada), F. Hoffmann-La Roche, Ltd. (Switzerland), Genentech, Inc. (U.S.), Genomictree, Inc. (South Korea), HTG Molecular Diagnostics, Inc. (U.S.), Illumina, Inc. (U.S.), Integragen (France), Laboratory Corporation of America Holdings (U.S.), Luminex Corporation (U.S.), Molecular MD Corp. (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Oxford Biodynamics Plc (U.K), PacBio (U.S.), PerkinElmer Inc. (U.S.), Qiagen (Germany), Thermo Fisher Scientific, Inc. (U.S.)

Market Opportunities

  • Increase in the number of patients seeking genetic counselling and testing
  • Rise in the prevalence of infertility

Market Definition

Cardiovascular genetic testing the broader genetic testing industry that focuses on the testing, analysis, and interpretation of an individual's genetic information to identify genetic factors and mutations associated with cardiovascular diseases and conditions. Cardiovascular genetic testing provides insights into an individual's genetic predisposition to various heart and vascular conditions. Cardiomyopathies, arrhythmic disorders, thoracic aortic aneurysms and dissections, and familial hypercholesterolemia (FH) are among the inherited cardiovascular diseases for which genetic testing is instructive and beneficial.

Global Cardiovascular Genetic Testing Market Dynamics

Drivers

  • Growing Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including coronary artery disease, hypertension, and heart failure, remain major global health concerns. The increasing prevalence of these conditions has heightened the need for genetic testing to identify at-risk individuals and guide prevention and treatment strategies. Cardiovascular genetic testing can identify genetic factors that increase the risk of heart diseases, even before clinical symptoms appear. This early detection allows for preventive measures and lifestyle modifications to mitigate disease risk.

  • Wellness and Preventive Health Initiatives

As preventive healthcare gains importance, individuals are more interested in understanding their genetic risk factors to take proactive measures in maintaining cardiovascular health. Wellness and preventive health initiatives promote awareness of the importance of proactive healthcare. Individuals are becoming more conscious of the need to monitor their health and take preventive measures to reduce the risk of diseases. Preventive healthcare is gaining prominence over reactive healthcare. People are looking for ways to identify health risks early and take action to prevent diseases, including cardiovascular conditions.

Opportunity

  • Preventive Healthcare Initiatives and Measures

Preventive healthcare is becoming a priority for individuals and healthcare systems. Genetic testing is a valuable tool for preventive measures, helping individuals make informed decisions about their cardiovascular health. Preventive healthcare initiatives emphasize the importance of early detection and risk assessment. Cardiovascular genetic testing allows individuals to identify their genetic predisposition to heart diseases at an early stage, enabling timely interventions and preventive measures.

Restraint/Challenge

  • Ethical and Privacy Concerns

Genetic testing raises ethical questions regarding the privacy and security of individuals genetic information. Concerns about how genetic data may be used or shared can discourage some individuals from participating in testing. Genetic testing involves the collection of highly sensitive personal information, including an individual's genetic code. Concerns about data privacy and security have increased as data breaches and misuse of personal information become more prevalent. Patients may be hesitant to undergo testing if they fear their genetic data could be exposed or misused.

This global cardiovascular genetic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cardiovascular genetic testing market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In November 2020, the FDA expanded the approval of a cancer blood test known as "liquid biopsy," which detects genetic alterations in tumour DNA in the blood and can help match patients to appropriate treatments
  • In August 2020, the FDA authorised Guardant360 CDx and FoundationOne Liquid CDx from Guardant Health and Foundation Medicine for use as companion diagnostic tests and general tumour profiling

Global Cardiovascular Genetic Testing Market Scope

The global cardiovascular genetic testing market is segmented on the basis of disease, technology, testing type, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease

  • Inherited Cardiomyopathies
  • Hypertrophic Cardiomyopathy (HCM)
  • Dilated Cardiomyopathy (DCM)
  • Arrhythmia
  • Aortopathies
  • Others

Technology

  • Cytogenetic Testing
  • Biochemical Testing
  • Molecular Testing

Testing Type

  • Predictive Testing
  • Carrier Testing
  • Prenatal and Newborn Testing
  • Diagnostic Testing
  • Pharmacogenomic Testing
  • Others

Application

  • Chromosome Analysis
  • Genetic Disease Diagnosis
  • Cardiovascular Disease Diagnosis
  • Others

Global Cardiovascular Genetic Testing Market Regional Analysis/Insights

The global cardiovascular genetic testing market is analysed and market size insights and trends are provided by country, disease, technology, testing type, and application as referenced above.

The countries covered in the global cardiovascular genetic testing market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global cardiovascular genetic testing market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having chronic diseases.

Asia-Pacific is expected to witness significant growth in the global cardiovascular genetic testing market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for chronic diseases, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global cardiovascular genetic testing market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global cardiovascular genetic testing market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on global cardiovascular genetic testing market. The data is available for the historic period of 2015-2020.

Competitive Landscape and Global Cardiovascular Genetic Testing Market Share Analysis

The global cardiovascular genetic testing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global cardiovascular genetic testing market.

Some of the major players operating in the global cardiovascular genetic testing market are:

  • Abbott (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • Danaher (U.S.)
  • Daan Gene Co., Ltd. (Canada)
  • F. Hoffmann-La Roche, Ltd. (Switzerland)
  • Genentech, Inc. (U.S.)
  • Genomictree, Inc. (South Korea)
  • HTG Molecular Diagnostics, Inc. (U.S.)
  • Illumina, Inc. (U.S.)
  • Integragen (France)
  • Laboratory Corporation of America Holdings (U.S.)
  • Luminex Corporation (U.S.)
  • Molecular MD Corp. (U.S.)
  • Myriad Genetics, Inc. (U.S.)
  • Natera, Inc. (U.S.)
  • Oxford Biodynamics Plc (U.K)
  • PacBio (U.S.)
  • PerkinElmer Inc. (U.S.)
  • Qiagen (Germany)
  • Thermo Fisher Scientific, Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The cardiovascular genetic testing market size will be worth USD 17,152.16 million by 2030.
The growth rate of the cardiovascular genetic testing market is 11.2% in the forecast period by 2030.
The growing prevalence of cardiovascular diseases & wellness and preventive health initiatives are the growth drivers of the cardiovascular genetic testing market.
Disease, technology, testing type, and application are the factors on which the cardiovascular genetic testing market research is based.
Major companies in the cardiovascular genetic testing market are Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher (U.S.), Daan Gene Co., Ltd. (Canada), F. Hoffmann-La Roche, Ltd. (Switzerland), Genentech, Inc. (U.S.), Genomictree, Inc. (South Korea), HTG Molecular Diagnostics, Inc. (U.S.), Illumina, Inc. (U.S.), Integragen (France), Laboratory Corporation of America Holdings (U.S.), Luminex Corporation (U.S.), Molecular MD Corp. (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Oxford Biodynamics Plc (U.K), PacBio (U.S.), PerkinElmer Inc. (U.S.), Qiagen (Germany), Thermo Fisher Scientific, Inc. (U.S.)
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials